Gene mutation analysis and immunohistochemical study of β-catenin in odontogenic tumors
Article first published online: 10 NOV 2006
Volume 56, Issue 12, pages 732–737, December 2006
How to Cite
Miyake, T., Tanaka, Y., Kato, K., Tanaka, M., Sato, Y., Ijiri, R., Inayama, Y., Ito, Y., Aoki, S., Kawabe, R. and Tohnai, I. (2006), Gene mutation analysis and immunohistochemical study of β-catenin in odontogenic tumors. Pathology International, 56: 732–737. doi: 10.1111/j.1440-1827.2006.02039.x
- Issue published online: 10 NOV 2006
- Article first published online: 10 NOV 2006
- Received 13 April 2006. Accepted for publication 17 August 2006.
- odontogenic tumor
In the present study the significance of nuclear/cytoplasmic expression of β-catenin (CTNNB1) and mutation of the CTNNB1 gene (CTNNB1) in odontogenic tumors was examined. Six ameloblastomas (five follicular ameloblastomas and one plexiform ameloblastoma) and three malignant odontogenic tumors (one metastasizing ameloblastoma, one ameloblastic carcinoma, and one primary intraosseous odontogenic carcinoma) were investigated for CTNNB1 expression and CTNNB1 mutation. Immunohistochemically, all follicular ameloblastomas and one primary intraosseous odontogenic carcinoma exhibited focal and moderate nuclear/cytoplasmic expression of CTNNB1, whereas the plexiform ameloblastoma and the remaining two malignant odontogenic tumors had entirely membranous expression. CTNNB1 mutation at codon 40 of exon 3 was found in one of the six follicular ameloblastomas. The other five follicular ameloblastomas, the plexiform ameloblastoma, and the three malignant odontogenic tumors did not show mutation in exon 3 of CTNNB1. These findings further confirmed that CTNNB1 mutation is not frequent in ameloblastoma and malignant odontogenic tumors, although the abnormality of Wnt signaling may be associated with some of these tumors.